PDGFRB (Platelet Derived Growth Factor Receptor Beta)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

5159

Related tests:

PDGFRB fusion	Childhood B Acute Lymphoblastic Leukemia	PDGFRB fusion	Childhood B Acute Lymphoblastic Leukemia	dasatinib Sensitive: C3 – Early Trials dasatinib Sensitive : C3	dasatinib Sensitive: C3 – Early Trials dasatinib Sensitive : C3
PDGFRB overexpression	Colorectal Cancer	PDGFRB overexpression	Colorectal Cancer	ARO-002 Sensitive: C3 – Early Trials ARO-002 Sensitive : C3	ARO-002 Sensitive: C3 – Early Trials ARO-002 Sensitive : C3
PDGFRB mutation	Non Small Cell Lung Cancer	PDGFRB mutation	Non Small Cell Lung Cancer	nintedanib Sensitive: C3 – Early Trials nintedanib Sensitive : C3	nintedanib Sensitive: C3 – Early Trials nintedanib Sensitive : C3
PDGFRB overexpression	Osteosarcoma	PDGFRB overexpression	Osteosarcoma	anlotinib Sensitive: C3 – Early Trials anlotinib Sensitive : C3	anlotinib Sensitive: C3 – Early Trials anlotinib Sensitive : C3
KDR overexpression + PDGFRB overexpression	Osteosarcoma	KDR overexpression + PDGFRB overexpression	Osteosarcoma	anlotinib Sensitive: C3 – Early Trials anlotinib Sensitive : C3	anlotinib Sensitive: C3 – Early Trials anlotinib Sensitive : C3
ALK expression + PDGFRB expression	Lymphoma	ALK expression + PDGFRB expression	Lymphoma	imatinib Sensitive: C3 – Early Trials imatinib Sensitive : C3	imatinib Sensitive: C3 – Early Trials imatinib Sensitive : C3
PDGFRB underexpression	Sarcoma	PDGFRB underexpression	Sarcoma	pazopanib Resistant: C4 – Case Studies pazopanib Resistant : C4	pazopanib Resistant: C4 – Case Studies pazopanib Resistant : C4
PDGFRB overexpression	Sarcoma	PDGFRB overexpression	Sarcoma	pazopanib Sensitive: C4 – Case Studies pazopanib Sensitive : C4	pazopanib Sensitive: C4 – Case Studies pazopanib Sensitive : C4
EBF1-PDGFRB fusion	B Acute Lymphoblastic Leukemia	EBF1-PDGFRB fusion	B Acute Lymphoblastic Leukemia	imatinib Sensitive: C4 – Case Studies imatinib Sensitive : C4	imatinib Sensitive: C4 – Case Studies imatinib Sensitive : C4
PDGFRB overexpression	Thyroid Gland Papillary Carcinoma	PDGFRB overexpression	Thyroid Gland Papillary Carcinoma	larotrectinib Sensitive: C4 – Case Studies larotrectinib Sensitive : C4	larotrectinib Sensitive: C4 – Case Studies larotrectinib Sensitive : C4
ATF7IP-PDGFRB fusion	Acute Lymphocytic Leukemia	ATF7IP-PDGFRB fusion	Acute Lymphocytic Leukemia	dasatinib Sensitive: C4 – Case Studies dasatinib Sensitive : C4	dasatinib Sensitive: C4 – Case Studies dasatinib Sensitive : C4
PCM1-PDGFRB fusion	Myelodysplastic Syndrome	PCM1-PDGFRB fusion	Myelodysplastic Syndrome	imatinib Sensitive: C4 – Case Studies imatinib Sensitive : C4	imatinib Sensitive: C4 – Case Studies imatinib Sensitive : C4
CCDC88C-PDGFRB fusion	Lymphoma	CCDC88C-PDGFRB fusion	Lymphoma	imatinib Sensitive: C4 – Case Studies imatinib Sensitive : C4	imatinib Sensitive: C4 – Case Studies imatinib Sensitive : C4
ATF7IP-PDGFRB fusion	B Acute Lymphoblastic Leukemia	ATF7IP-PDGFRB fusion	B Acute Lymphoblastic Leukemia	Tyrosine kinase inhibitor Sensitive: C4 – Case Studies Tyrosine kinase inhibitor Sensitive : C4	Tyrosine kinase inhibitor Sensitive: C4 – Case Studies Tyrosine kinase inhibitor Sensitive : C4
ATF7IP-PDGFRB translocation	B Acute Lymphoblastic Leukemia	ATF7IP-PDGFRB translocation	B Acute Lymphoblastic Leukemia	dasatinib Sensitive: C4 – Case Studies dasatinib Sensitive : C4	dasatinib Sensitive: C4 – Case Studies dasatinib Sensitive : C4
PDGFRB overexpression	Hepatocellular Cancer	PDGFRB overexpression	Hepatocellular Cancer	Tyrosine kinase inhibitor Sensitive: D – Preclinical Tyrosine kinase inhibitor Sensitive : D	Tyrosine kinase inhibitor Sensitive: D – Preclinical Tyrosine kinase inhibitor Sensitive : D
PDGFRB overexpression	Melanoma	PDGFRB overexpression	Melanoma	vemurafenib Resistant: D – Preclinical vemurafenib Resistant : D	vemurafenib Resistant: D – Preclinical vemurafenib Resistant : D
EBF1-PDGFRB fusion	Childhood B Acute Lymphoblastic Leukemia	EBF1-PDGFRB fusion	Childhood B Acute Lymphoblastic Leukemia	dasatinib Sensitive: D – Preclinical dasatinib Sensitive : D	dasatinib Sensitive: D – Preclinical dasatinib Sensitive : D
ETV6-PDGFRB fusion	Acute Lymphocytic Leukemia	ETV6-PDGFRB fusion	Acute Lymphocytic Leukemia	YD312 Sensitive: D – Preclinical YD312 Sensitive : D	YD312 Sensitive: D – Preclinical YD312 Sensitive : D
AGGF1-PDGFRB fusion	Acute Lymphocytic Leukemia	AGGF1-PDGFRB fusion	Acute Lymphocytic Leukemia	imatinib Resistant: D – Preclinical imatinib Resistant : D	imatinib Resistant: D – Preclinical imatinib Resistant : D
AGGF1-PDGFRB fusion	Acute Lymphocytic Leukemia	AGGF1-PDGFRB fusion	Acute Lymphocytic Leukemia	dasatinib Resistant: D – Preclinical dasatinib Resistant : D	dasatinib Resistant: D – Preclinical dasatinib Resistant : D
AGGF1-PDGFRB fusion	Acute Lymphocytic Leukemia	AGGF1-PDGFRB fusion	Acute Lymphocytic Leukemia	nilotinib Resistant: D – Preclinical nilotinib Resistant : D	nilotinib Resistant: D – Preclinical nilotinib Resistant : D
PDGFRB C843G	Acute Lymphocytic Leukemia	PDGFRB C843G	Acute Lymphocytic Leukemia	imatinib Resistant: D – Preclinical imatinib Resistant : D	imatinib Resistant: D – Preclinical imatinib Resistant : D
PDGFRB C843G	Acute Lymphocytic Leukemia	PDGFRB C843G	Acute Lymphocytic Leukemia	dasatinib Resistant: D – Preclinical dasatinib Resistant : D	dasatinib Resistant: D – Preclinical dasatinib Resistant : D
PDGFRB C843G	Acute Lymphocytic Leukemia	PDGFRB C843G	Acute Lymphocytic Leukemia	ponatinib Resistant: D – Preclinical ponatinib Resistant : D	ponatinib Resistant: D – Preclinical ponatinib Resistant : D
PDGFRB C843G	Acute Lymphocytic Leukemia	PDGFRB C843G	Acute Lymphocytic Leukemia	nilotinib Resistant: D – Preclinical nilotinib Resistant : D	nilotinib Resistant: D – Preclinical nilotinib Resistant : D
PDGFRB C843G	Acute Lymphocytic Leukemia	PDGFRB C843G	Acute Lymphocytic Leukemia	CHZ868 Sensitive: D – Preclinical CHZ868 Sensitive : D	CHZ868 Sensitive: D – Preclinical CHZ868 Sensitive : D
ATF7IP-PDGFRB fusion	Acute Lymphocytic Leukemia	ATF7IP-PDGFRB fusion	Acute Lymphocytic Leukemia	imatinib Sensitive: D – Preclinical imatinib Sensitive : D	imatinib Sensitive: D – Preclinical imatinib Sensitive : D

PDGFRB (Platelet Derived Growth Factor Receptor Beta)

Associations(28)

Associations
(28)